A 385358
CAS No. 406228-55-5
A 385358( A385358 )
Catalog No. M14400 CAS No. 406228-55-5
A 385358 is a potent, selective, cell-permeable Bcl-XL inhibitor with Ki of 0.8 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 176 | Get Quote |
|
| 10MG | 266 | Get Quote |
|
| 25MG | 461 | Get Quote |
|
| 50MG | 669 | Get Quote |
|
| 100MG | 945 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameA 385358
-
NoteResearch use only, not for human use.
-
Brief DescriptionA 385358 is a potent, selective, cell-permeable Bcl-XL inhibitor with Ki of 0.8 nM.
-
DescriptionA 385358 is a potent, selective, cell-permeable Bcl-XL inhibitor with Ki of 0.8 nM, displays >80-fold selectivity over Bcl-2 (Ki=64 nM); shows relatively modest single-agent cytotoxic activity against most tumor cell lines with an EC50 of <500 nM in cells dependent on Bcl-X(L) for survival; enhances the in vitro cytotoxic activity of numerous chemotherapeutic agents; significantly inhibits tumor growth in the A549 xenograft model.
-
In VitroA-385358 is a selective inhibitor of Bcl-XL with Kis of 0.80 and 67 nM for Bcl-XL and Bcl-2, respectively, in fluorescence polarization assays. Treatment of IL-3-deprived FL5.12/Bcl-XL cells for 24 hours with A-385358 results in cell killing with an EC50 of 0.47±0.05 μM (n=68). This effect is accompanied by an increase in caspase-3 activity. Consistent with the greater affinity for the Bcl-XL versus Bcl-2 hydrophobic grooves, the EC50 of A-385358 for IL-3-depleted FL5.12/Bcl-2 cells (1.9±0.1 μM; n=55) is 4-fold higher relative to the cytokine-deprived FL5.12/Bcl-XL cells. In addition, A-385358 is more effective at stimulating cytochrome c release from mitochondria isolated from FL5.12/Bcl-XL versus Bcl-2 cells.
-
In VivoThe combination of A-385358 given at 100 mg/kg/d plus the lower dose of paclitaxel produces a significant reduction in tumor growth (%T/C) compare with paclitaxel monotherapy. This combination also yields a >100% increase in time for tumors to reach 900 mm3 (%ILS) compare with vehicle control. Maximal efficacy is observed during the dosing period for A-385358, with slow but steady increase in the tumor growth after termination of treatment. The combination of A-385358 at 75 mg/kg/d plus paclitaxel at 30 mg/kg/d is also well tolerated and inhibits tumor growth rate by nearly 80%. Significant effects on tumor growth relative to paclitaxel monotherapy are observed with doses as low as 50 mg/kg/d.
-
SynonymsA385358
-
PathwayAngiogenesis
-
TargetBcl-2
-
RecptorBcl-2
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number406228-55-5
-
Formula Weight639.83
-
Molecular FormulaC32H41N5O5S2
-
Purity>98% (HPLC)
-
SolubilityDMSO : 125 mg/mL195.36 mM
-
SMILESO=C(NS(=O)(C1=CC=C(N[C@H](CCN(C)C)CSC2=CC=CC=C2)C([N+]([O-])=O)=C1)=O)C3=CC=C(N4CCC(C)(C)CC4)C=C3
-
Chemical NameN-[4-[[(2R)-4-(Dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-(4,4-dimethylpiperidin-1-yl)benzamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Wendt MD, et al. J Med Chem. 2006 Feb 9;49(3):1165-81.
2. Shoemaker AR, et al. Cancer Res. 2006 Sep 1;66(17):8731-9.
molnova catalog
related products
-
Navitoclax
Navitoclax (ABT-263) is a potent, orally bioavailable Bcl-2 family inhibitor with Ki of <1 nM for Bcl-2, Bcl-xL, and Bcl-w.
-
DAN 004
A small molecule Bax inhibitor that inhibits Bax/Bak oligomerization and prevents mitochondrial outer membrane permeabilization (MOMP) with IC50 of 0.7 uM.
-
MCL-1/BCL-2-IN-2
MCL-1/BCL-2-IN-2 is a potent and selective dual inhibitor of Bcl-2 and Mcl-1.
Cart
sales@molnova.com